Rosenblatt-Velin Nathalie, Lepore Mario G, Cartoni Cristina, Beermann Friedrich, Pedrazzini Thierry
Department of Medicine, University of Lausanne Medical School, Lausanne, Switzerland. Swiss Institute for Experimental Cancer Research, Epalinges, Switzerland.
J Clin Invest. 2005 Jul;115(7):1724-33. doi: 10.1172/JCI23418. Epub 2005 Jun 9.
Recent evidence suggests that the heart possesses a greater regeneration capacity than previously thought. In the present study, we isolated undifferentiated precursors from the cardiac nonmyocyte cell population of neonatal hearts, expanded them in culture, and induced them to differentiate into functional cardiomyocytes. These cardiac precursors appear to express stem cell antigen-1 and demonstrate characteristics of multipotent precursors of mesodermal origin. Following infusion into normal recipients, these cells home to the heart and participate in physiological and pathophysiological cardiac remodeling. Cardiogenic differentiation in vitro and in vivo depends on FGF-2. Interestingly, this factor does not control the number of precursors but regulates the differentiation process. These findings suggest that, besides its angiogenic actions, FGF-2 could be used in vivo to facilitate the mobilization and differentiation of resident cardiac precursors in the treatment of cardiac diseases.
最近的证据表明,心脏具有比先前认为的更大的再生能力。在本研究中,我们从新生心脏的心脏非心肌细胞群体中分离出未分化的前体细胞,在培养中使其扩增,并诱导它们分化为功能性心肌细胞。这些心脏前体细胞似乎表达干细胞抗原-1,并表现出中胚层来源的多能前体细胞的特征。注入正常受体后,这些细胞归巢至心脏并参与生理性和病理性心脏重塑。体外和体内的心肌分化取决于FGF-2。有趣的是,该因子并不控制前体细胞的数量,而是调节分化过程。这些发现表明,除了其血管生成作用外,FGF-2可在体内用于促进驻留心脏前体细胞的动员和分化,以治疗心脏疾病。